Loading grant details…
Completed
RESEARCH
Europe PMC
Tralokinumab for treating moderate to severe atopic dermatitis (ID3734)
£328.1K
GBP
| Funder | National Institute for Health Research |
|---|---|
| Recipient Organization | Bmj Publishing Group Limited |
| Country | United Kingdom |
| Start Date | Apr 22, 2021 |
| End Date | Oct 07, 2021 |
| Duration | 168 days |
| Number of Grantees | 1 |
| Roles | Award Holder |
| Data Source | Europe PMC |
| Grant ID | NIHR134014 |
Grant Description
To appraise the clinical and cost effectiveness of tralokinumab within its marketing authorisation for treating moderate to severe atopic dermatitis.
All Grantees
Bmj Publishing Group Limited
Advertisement
Advertisement
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Start Year
2021
End Year
2021
Grantees
1
Related Grants
Lassa Fever Vaccine Efficacy And Prevention for West Africa...
European & Developing Countries Clinical...
€2.29M EUR
Platform Adaptive trial of NOvel antiviRals for eArly treatM...
National Institute for Health and Care R...
£2.14M GBP
The Swedish contribution to the construction and operation o...
Swedish Research Council
1.95M kr SEK
Advertisement
